PFE – Pfizer Inc.

Pfizer, Inc.

PFE

$28.08

Name : Pfizer, Inc.

Sector : Healthcare

Industry: Drug Manufacturers - General

Mark. Cap: $159,729,041,408.00

EPSttm : 1.36

Pfizer, Inc.

$28.08

1.12%

$0.31

PFE — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

2.31

Margin Of Safety %

Put/Call OI Ratio

0.82

EPS Next Q Diff

0.04

EPS Last/This Y

1.59

EPS This/Next Y

-0.14

Price

28.08

Target Price

28.52

Analyst Recom

2.59

Performance Q

12.32

Upside

-37.0%

Beta

0.38

Ticker: PFE

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-02	PFE	27.24	0.84	0.87	2584827
2026-03-04	PFE	26.59	0.84	1.20	2627029
2026-03-05	PFE	26.6	0.82	0.55	2633006
2026-03-09	PFE	26.81	0.78	0.48	2676651
2026-03-10	PFE	27.16	0.78	0.34	2694299
2026-03-11	PFE	27.29	0.78	0.58	2725336
2026-03-12	PFE	26.85	0.78	1.58	2746740
2026-03-17	PFE	27.48	0.78	0.64	2726401
2026-03-18	PFE	27.33	0.79	1.53	2782467
2026-03-19	PFE	27.45	0.82	0.37	2856748
2026-03-20	PFE	26.98	0.82	0.57	2879679
2026-03-23	PFE	26.79	0.86	0.84	2265318
2026-03-24	PFE	26.99	0.86	0.37	2318873
2026-03-25	PFE	27.31	0.86	0.27	2358980
2026-03-26	PFE	27.56	0.84	0.34	2390608
2026-03-27	PFE	27.04	0.84	0.61	2423188
2026-03-30	PFE	27.76	0.83	0.59	2318141
2026-03-31	PFE	28.01	0.82	0.26	2370853
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	PFE	27.23	-21.0	7899.1	2.96
2026-03-03	PFE	26.60	-20.9	7760.9	2.96
2026-03-04	PFE	26.59	-20.9	8140.0	2.96
2026-03-05	PFE	26.59	-20.9	7670.0	2.96
2026-03-06	PFE	27.04	-20.9	7940.6	2.96
2026-03-09	PFE	26.81	-20.9	9660.5	2.96
2026-03-10	PFE	27.16	-20.9	9990.2	2.96
2026-03-11	PFE	27.30	-20.9	9871.9	2.96
2026-03-12	PFE	26.86	-20.9	12655.0	2.96
2026-03-13	PFE	26.60	-20.9	9648.7	2.96
2026-03-17	PFE	27.48	-20.9	10281.5	2.96
2026-03-18	PFE	27.33	-20.9	9728.1	2.96
2026-03-19	PFE	27.42	-20.9	8752.7	2.96
2026-03-20	PFE	26.99	-20.9	8479.1	2.96
2026-03-23	PFE	26.78	-20.9	8597.7	2.96
2026-03-24	PFE	26.96	-20.9	8798.6	2.96
2026-03-25	PFE	27.31	-20.9	8882.5	2.96
2026-03-26	PFE	27.56	-20.9	8844.4	2.96
2026-03-27	PFE	27.03	-20.9	8420.4	2.96
2026-03-30	PFE	27.76	-20.9	9076.8	2.96
2026-03-31	PFE	28.08	-20.9	8857.8	2.96
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	PFE	0.00	0.33	2.58
2026-03-03	PFE	0.00	0.33	2.58
2026-03-04	PFE	0.00	0.33	2.58
2026-03-05	PFE	0.00	0.33	2.58
2026-03-06	PFE	0.00	0.33	2.58
2026-03-09	PFE	0.00	0.28	2.58
2026-03-10	PFE	0.00	0.28	2.58
2026-03-11	PFE	0.00	0.28	2.51
2026-03-12	PFE	0.00	0.28	2.51
2026-03-13	PFE	0.00	0.28	2.51
2026-03-17	PFE	0.00	0.25	2.51
2026-03-18	PFE	0.00	0.25	2.51
2026-03-19	PFE	0.00	0.25	2.51
2026-03-20	PFE	0.00	0.25	2.51
2026-03-23	PFE	0.00	0.24	2.51
2026-03-24	PFE	0.00	0.24	2.51
2026-03-25	PFE	0.00	0.24	2.31
2026-03-26	PFE	0.00	0.24	2.31
2026-03-27	PFE	0.00	0.24	2.31
2026-03-30	PFE	0.00	0.25	2.31
2026-03-31	PFE	0.00	0.25	2.31
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.66

Avg. EPS Est. Current Quarter

0.73

Avg. EPS Est. Next Quarter

0.7

Insider Transactions

Institutional Transactions

0.25

Beta

0.38

Average Sales Estimate Current Quarter

13905

Average Sales Estimate Next Quarter

14490

Fair Value

35.57

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

54.5

Max Drawdown 5-Year %

-59

Target Price

28.52

P/E

20.72

Forward P/E

9.96

PEG

P/S

2.55

P/B

1.85

P/Free Cash Flow

17.59

EPS

1.36

Average EPS Est. Cur. Y

2.96

EPS Next Y. (Est.)

2.82

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

12.38

Relative Volume

0.98

Return on Equity vs Sector %

-18.4

Return on Equity vs Industry %

-27.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

8857.8

◆ PFE Healthcare

$28.08

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

20/20

Pullback

8/25

Volume

7/15

Valuation

11/20

TP/AR

0/10

Options

4/10

RSI

Range 1M

85.3%

Sup Dist

2.6%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

14/25

Growth

2/30

Estimates

4/20

Inst/Vol

6/15

Options

7/10

EPS Yr

-8.2%

EPS NY

-4.6%

52W%

95.8%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟡 HOLD +23.6% upside

Quality

10/30

Valuation

15/30

Growth

3/25

Stability

4/10

LT Trend

4/5

Upside

+23.6%

Quality

MoS

27%

Pfizer, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 75000

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

PFE

Latest News

—

Caricamento notizie per PFE…

stock quote shares PFE – Pfizer Inc. Stock Price stock today

news today PFE – Pfizer Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch PFE – Pfizer Inc. yahoo finance google finance

stock history PFE – Pfizer Inc. invest stock market

stock prices PFE premarket after hours

ticker PFE fair value insiders trading

PFE – Pfizer Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: PFE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y